Photosensitivity Reactions to Vandetanib: Redevelopment after Sequential Treatment with Docetaxel
Annals of Dermatology
; : S314-S318, 2011.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-165622
Biblioteca responsável:
WPRO
ABSTRACT
Vandetanib (ZD6474, Zactima(TM)) is a novel, orally available inhibitor of different intracellular signaling pathways involved in tumor growth, progression, and angiogenesis, including vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and rearranged during transfection tyrosine kinase activity. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QC interval prolongation, and hypertension. In a few randomized, double-blinded studies, cutaneous adverse events including these general symptoms have been reported, but there are only a few reports on the photosensitivity reaction to vandetanib domestically as conducted by dermatologists. In this report, we describe two cases of photosensitivity reactions induced by vandetanib. After improvement with steroid and antihistamine, the photosensitivity reaction was redeveloped by sequential treatment with docetaxel.
Texto completo:
Disponível
Contexto em Saúde:
Doenças Negligenciadas
Problema de saúde:
Diarreia
/
Doenças Negligenciadas
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Piperidinas
/
Quinazolinas
/
Proteínas Tirosina Quinases
/
Transfecção
/
Receptor 2 de Fatores de Crescimento do Endotélio Vascular
/
Taxoides
/
Diarreia
/
Receptores ErbB
/
Hipertensão
Tipo de estudo:
Ensaio clínico controlado
Idioma:
Inglês
Revista:
Annals of Dermatology
Ano de publicação:
2011
Tipo de documento:
Artigo